Skip to content
Open access

Ginsenoside Rg2 attenuates Alzheimer-like phenotypes in 3xTg-AD mice: Associations with gut microbiota and brain metabolomic profiles.

Aug 2026 · Phytomedicine · Vol 160, pp. 158678 · 0 citations · 69 references
Medicine

TL;DR

Multi-omics evidence is provided supporting the potential of Rg2 as a natural product for AD intervention and its associations with gut microbiota and brain metabolism.

Abstract

Background

AND

Purpose

Alzheimer's disease (AD) is the most common form of dementia. The microbiota-gut-brain axis represents a critical pathway bridging peripheral metabolic signals and central AD pathology. This study aimed to evaluate the effects of ginsenoside Rg2 on AD-like phenotypes in 3xTg-AD mice and to examine its associations with gut microbiota and brain metabolomic profiles. STUDY

Design

AND

Methods

A 3xTg-AD mouse model was used to assess the effects of Rg2 intervention in vivo. Behavioral performance was assessed using open field and water maze tests, Aβ and inflammatory factors were detected by ELISA, gut microbial changes were analyzed by 16S rRNA sequencing, and brain metabolic alterations were investigated using untargeted metabolomics.

Results

The results showed that Rg2 improved behavioral performance in mice, reduced Aβ deposition in the brain, and decreased serum and brain tissue inflammatory factors. Rg2 treatment was associated with alterations in gut microbial community characteristics. Metabolomics indicated that Rg2 was associated with alterations in the brain metabolic profile, with differential metabolites mainly involved in energy and lipid metabolism as well as inflammation-related pathways. The correlation network further revealed a close relationship between microbiota, SCFAs and brain metabolites, inflammation and behavioral indicators.

Conclusion

Rg2 attenuated AD-related pathology and functional impairment in 3xTg-AD mice. These protective effects were accompanied by changes in gut microbiota composition, brain metabolic profiles, and the inflammatory microenvironment. This study provides multi-omics evidence supporting the potential of Rg2 as a natural product for AD intervention and highlights its associations with gut microbiota and brain metabolism.

Read PDF

Similar papers

Open access Aug 2026

Astragalus polysaccharide alleviates neuropathology and cognitive deficits by modulating gut microbiota and neuroinflammation in an Alzheimer’s disease model

Findings demonstrate that APS alleviates cognitive deficits and AD-like pathology, partially through remodeling gut microbiota and modulating the gut-brain axis, and represents a promising natural compound-based therapeutic candidate for managing cognitive decline associated with Alzheimer’s disease.

Xiaolin Cui, Zhen Wei, Qingshui Wang et al. · 0 citations
Open access Aug 2026

LC-MS-based metabolomics reveals the In Vivo effects of cognitive formula 1 in rats with Aβ-induced Alzheimer’s disease

Results indicated that synergistic interactions among multiple CF1 components influence host metabolic pathways, in particular those involved in glycerophospholipid and amino acid metabolism, thereby suggesting an explanation for the alleviation of systemic metabolic dysregulation by the formulation.

Di Wu, Yanling Lin, Wenjun Guo et al. · 0 citations
Oct 2026

Probiotics Attenuate AlCl₃-Induced Alzheimer's Disease via Gut-Brain Axis Modulation and Suppression of NF-κB/NLRP3 Neuroinflammation.

Disruptions along the brain-gut-microbiota axis significantly contribute to Alzheimer's disease (AD) pathogenesis. This study evaluated the therapeutic potential of a multi-strain probiotic mixture in mitigating cognitive decline, neuroinflammation, and amyloid pathology in an AD rat model. In the present study, after...

Asmaa M. Elfiky, Eman M. Shahy, A. Mahmoud · 0 citations
Open access Aug 2026

Breaking Alzheimer's Disease Barrier: The Role of Xanthoceras sorbifolia Bunge Oil in Gut-Brain Axis and TLR4/Myd88/MAPK Pathway Inhibition.

XSBO alleviates AD-related cognitive impairment and neuroinflammation by modulating the gut microbiota-SCFA axis and inhibiting TLR4/MyD88/MAPK-mediated inflammatory responses, and suggest that XSBO may serve as a promising dietary intervention for neurodegenerative disease management.

Li-Jing Du, Shi-Kai Yan, Xiaopeng Ren et al. · 0 citations
Open access Oct 2026

Rifaximin ameliorates memory impairment and Alzheimer's pathological changes in APP/PS1 mice associated with changes in the gut microbiome-bile acids-serum metabolites networks.

BACKGROUND AND PURPOSE Modifying the brain-gut-microbiota axis has emerged as a promising therapeutic strategy against Alzheimer's disease (AD). Whether rifaximin, a non-absorbed and non-systemic antibiotic, can be applied to the treatment of AD remains unexplored. In this study, we investigated the effects of rifaximi...

Di Wu, Mei-Tong Nie, Ji-Xian Lin et al. · 0 citations
Sep 2026

Ginseng-Schisandra ameliorates D-galactose-induced cognitive impairment in mice: Evidence from gut microbiota and metabolomic analyses.

Age-related cognitive decline is associated with oxidative stress, systemic inflammation, gut microbial dysbiosis, and metabolic disturbance. This study characterized the chemical profile of a Panax ginseng-Schisandra chinensis co-decoction (TG) and evaluated its effects in a D-galactose-treated mouse model. Chemical c...

Ya-Ran Teng, Qiu-Min Huang, Shu-Qi Zhang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.